Interleukin-2-inducible T-cell Kinase (ITK) Targeting by BMS-509744 Does Not Affect Cell Viability in T-cell Prolymphocytic Leukemia (T-PLL)
Open Access
- 1 April 2015
- journal article
- Published by Elsevier BV in Journal of Biological Chemistry
- Vol. 290 (16), 10568-10569
- https://doi.org/10.1074/jbc.l115.644641
Abstract
No abstract availableThis publication has 6 references indexed in Scilit:
- Targeting Interleukin-2-inducible T-cell Kinase (ITK) and Resting Lymphocyte Kinase (RLK) Using a Novel Covalent Inhibitor PRN694Journal of Biological Chemistry, 2015
- Integrated genomic sequencing reveals mutational landscape of T-cell prolymphocytic leukemiaBlood, 2014
- T-Cell Receptor Signaling in Peripheral T-Cell Lymphoma – A Review of Patterns of Alterations in a Central Growth Regulatory PathwayCurrent Hematologic Malignancy Reports, 2013
- Inhibitors of BTK and ITK: State of the New Drugs for Cancer, Autoimmunity and Inflammatory DiseasesScandinavian Journal of Immunology, 2013
- Advances in the design of ITK inhibitorsExpert Opinion on Drug Discovery, 2013
- High TCL1 expression and intact T-cell receptor signaling define a hyperproliferative subset of T-cell prolymphocytic leukemiaBlood, 2008